Henning Helmke
Corporate Officer/Principal chez Göhmann Rechtsanwälte Partnergesellschaft
Postes actifs de Henning Helmke
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Göhmann Rechtsanwälte Partnergesellschaft | Corporate Officer/Principal | 14/05/2010 | - |
Historique de carrière de Henning Helmke
Anciens postes connus de Henning Helmke
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
KeyNeurotek Pharmaceuticals AG
 KeyNeurotek Pharmaceuticals AG Pharmaceuticals: OtherHealth Technology KeyNeurotek Pharmaceuticals AG is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal and autoimmune diseases. KeyNeurotek’s drug portfolio covers the entire drug development chain from research stage to advanced clinical development. At present, two compounds are in clinical development, KN38-7271 and KN203, both addressing significant markets such as traumatic brain injury, TBI, stroke, and urinary incontinence/overactive bladder. The company’s product development is based on its proprietary technology platform, which has been specifically tailored to diseases of the central nervous system, TELOMICS. KeyNeurotek was founded by Dr Frank Striggow, Frank Baumgart, Prof Dr Klaus G. Reymann and Prof Dr Henning Scheich in May 2000. The company is located in Magdeburg, Germany. | Directeur/Membre du Conseil | 31/08/2009 | 03/08/2011 |
Formation de Henning Helmke
| Eberhard Karls Universität Tübingen | Undergraduate Degree |
| University of Geneva | Undergraduate Degree |
| Université Paris 8 Vincennes Saint-Denis | Undergraduate Degree |
| University of Gottingen | Graduate Degree |
Statistiques
Internationale
| Allemagne | 5 |
| Suisse | 2 |
| France | 2 |
Opérationnelle
| Undergraduate Degree | 3 |
| Director/Board Member | 1 |
| Graduate Degree | 1 |
Sectorielle
| Consumer Services | 5 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
KeyNeurotek Pharmaceuticals AG
KeyNeurotek Pharmaceuticals AG Pharmaceuticals: OtherHealth Technology KeyNeurotek Pharmaceuticals AG is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal and autoimmune diseases. KeyNeurotek’s drug portfolio covers the entire drug development chain from research stage to advanced clinical development. At present, two compounds are in clinical development, KN38-7271 and KN203, both addressing significant markets such as traumatic brain injury, TBI, stroke, and urinary incontinence/overactive bladder. The company’s product development is based on its proprietary technology platform, which has been specifically tailored to diseases of the central nervous system, TELOMICS. KeyNeurotek was founded by Dr Frank Striggow, Frank Baumgart, Prof Dr Klaus G. Reymann and Prof Dr Henning Scheich in May 2000. The company is located in Magdeburg, Germany. | Health Technology |
| Göhmann Rechtsanwälte Partnergesellschaft |
- Bourse
- Insiders
- Henning Helmke
- Expérience
